More than 1,000 clinicians from over 400 sites across Europe, the Middle East, and South Africa have been trained in the 4 months since the launch of Systagenix’s (Gatwick, UK) WOUNDCHEK™ Protease Status, the world’s first point of care test for Elevated Protease Activity (EPA) in chronic wounds.

  The introduction of WOUNDCHEK Protease Status is a much-awaited adjunct to current clinical diagnosis and assessment, as EPA cannot be detected by visual cues. Recent clinical trial data has shown that a chronic wound with EPA has a 90% probability of not healing without appropriate intervention to lower protease activity. Twenty-eight percent of the non-healing wounds in the clinical trials had EPA. With WOUNDCHEK Protease Status clinicians will be able to identify these patients as soon as possible and prescribe the appropriate therapy, instead of going undetected and potentially not healing for months or years.

  WOUNDCHEK Protease Status is not currently cleared by FDA for sale within the US market.

  Visit http://www.systagenix.co.uk for more information.